Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
643 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02884726 | Phase 1 Study of Mesothelin-ADC | completed | Phase 1 | 8 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 19, 2020 | clinicaltrials |
| NCT02011945 | A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 7 | Mar 18, 2020 | clinicaltrials |
| NCT01653470 |
| completed |
| Phase 1 |
| 141 |
| Bristol-Myers SquibbINDUSTRY |
| 3 |
| Jan 28, 2020 |
| clinicaltrials |
| NCT01292655 | Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 94 | Bristol-Myers SquibbINDUSTRY | 3 | Jan 27, 2020 | clinicaltrials |
| NCT00636168 | Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma | completed | Phase 3 | 1,211 | Bristol-Myers SquibbINDUSTRY | 19 | Dec 17, 2019 | clinicaltrials |
| NCT00908752 | Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC(BRISK TA) | completed | Phase 3 | 734 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 2, 2019 | clinicaltrials |
| NCT04161911 | A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy | completed | — | 1,426 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 13, 2019 | clinicaltrials |
| NCT03165422 | A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan | completed | — | 68 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 23, 2019 | clinicaltrials |
| NCT00825955 | Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment(BRISK PS) | completed | Phase 3 | 587 | Bristol-Myers SquibbINDUSTRY | 19 | Oct 9, 2019 | clinicaltrials |
| NCT02279732 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin | completed | Phase 3 | 342 | Bristol-Myers SquibbINDUSTRY | 6 | Aug 28, 2019 | clinicaltrials |
| NCT02279862 | Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive | completed | Phase 2 | 82 | Bristol-Myers SquibbINDUSTRY | 9 | Aug 28, 2019 | clinicaltrials |
| NCT02976493 | Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma | completed | — | 500 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 20, 2019 | clinicaltrials |
| NCT02949895 | Study of BMS-986012 in Subjects With Small Cell Lung Caner | completed | Phase 1 | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 12, 2019 | clinicaltrials |
| NCT03448497 | Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom | completed | — | 333 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 6, 2019 | clinicaltrials |
| NCT01236352 | Multiple Ascending Dose of BMS-911543 | terminated | Phase 1 / Phase 2 | 98 | Bristol-Myers SquibbINDUSTRY | 2 | Jul 31, 2019 | clinicaltrials |
| NCT01515189 | Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab | completed | Phase 3 | 831 | Bristol-Myers SquibbINDUSTRY | 22 | Jul 31, 2019 | clinicaltrials |
| NCT01363817 | Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma | completed | Phase 1 | 31 | Bristol-Myers SquibbINDUSTRY | 3 | Jul 30, 2019 | clinicaltrials |
| NCT02159365 | Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients | completed | Phase 2 | 84 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT03192943 | A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors | completed | Phase 1 | 11 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 1, 2019 | clinicaltrials |
| NCT02492815 | PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma | completed | — | 1,773 | Bristol-Myers SquibbINDUSTRY | 16 | Jan 30, 2019 | clinicaltrials |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 30, 2019 | clinicaltrials |
| NCT02472977 | Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors(CXCessoR4) | terminated | Phase 1 / Phase 2 | 61 | Bristol-Myers SquibbINDUSTRY | 2 | Nov 1, 2018 | clinicaltrials |
| NCT02763761 | An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 9, 2018 | clinicaltrials |
| NCT01673854 | Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma | completed | Phase 2 | 70 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00527735 | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 334 | Bristol-Myers SquibbINDUSTRY | 8 | Jul 18, 2018 | clinicaltrials |
| NCT01478048 | Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 185 | Bristol-Myers SquibbINDUSTRY | 5 | May 21, 2018 | clinicaltrials |
| NCT03504696 | Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma | completed | — | 400 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 27, 2018 | clinicaltrials |
| NCT03048136 | A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer(CheckMate 955) | withdrawn | Phase 3 | 0 | Bristol-Myers SquibbINDUSTRY | 5 | Apr 17, 2018 | clinicaltrials |
| NCT03205722 | The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany | withdrawn | — | 0 | Bristol-Myers SquibbINDUSTRY | 0 | Apr 9, 2018 | clinicaltrials |
| NCT02845089 | Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab Emirates | completed | — | 382 | Bristol-Myers SquibbINDUSTRY | 0 | Mar 22, 2018 | clinicaltrials |
| NCT03346837 | A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects | completed | Phase 1 | 53 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 28, 2018 | clinicaltrials |
| NCT03438279 | Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy | completed | — | 600 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 19, 2018 | clinicaltrials |
| NCT01241292 | Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone | completed | Phase 1 | 7 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 15, 2018 | clinicaltrials |
| NCT03199846 | Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States | completed | — | 650 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 6, 2018 | clinicaltrials |
| NCT01441973 | Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma | completed | Phase 2 | 41 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
| NCT03312426 | An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants | completed | Phase 1 | 32 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 19, 2018 | clinicaltrials |
| NCT03247283 | Pharmacokinetics and Metabolism Study in Healthy Male Participants | completed | Phase 1 | 9 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 6, 2017 | clinicaltrials |
| NCT02252263 | A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma | completed | Phase 1 | 44 | Bristol-Myers SquibbINDUSTRY | 2 | Nov 1, 2017 | clinicaltrials |
| NCT03165409 | Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread | completed | — | 1,828 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 5, 2017 | clinicaltrials |
| NCT03161145 | A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread | completed | — | 297 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 3, 2017 | clinicaltrials |
| NCT02286219 | Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab) | completed | Phase 1 | 30 | Bristol-Myers SquibbINDUSTRY | 2 | Sep 18, 2017 | clinicaltrials |
| NCT02389972 | Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study | completed | — | 128 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 11, 2017 | clinicaltrials |
| NCT01696045 | Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma | terminated | Phase 2 | 14 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 29, 2017 | clinicaltrials |
| NCT01393964 | Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 3, 2017 | clinicaltrials |
| NCT02546791 | Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study(PASS) | completed | — | 101 | Bristol-Myers SquibbINDUSTRY | 0 | Jul 26, 2017 | clinicaltrials |
| NCT02928263 | Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents | withdrawn | — | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 17, 2017 | clinicaltrials |
| NCT02739386 | Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases | completed | — | 370 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 27, 2017 | clinicaltrials |
| NCT02705833 | Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada | completed | — | 591 | Bristol-Myers SquibbINDUSTRY | 0 | Apr 24, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials